Drug
Jsb462
Jsb462: highest development phase Phase 2, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| JSB462 NCT06991556 | Phase 2 | Metastatic Hormone-sensitive Prostate Cancer |
Latest
No recent events.
Follow Jsb462 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.